ARCHIVES

Phase IIb Trial of CRLX101 Fails Overall Survival Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

Sharfstein To Leave FDA

January 7, 2011

Knowing Tumor Cell Structure Improves Treatment Decisions

March 27, 2009

Panel Unenthused About New Toxicity Testing Program

December 15, 1978

Officals: “Separations” in Normal Range as Critics Claim Brain Drain in the Clinic

January 17, 2014

CCRU RFA Reissued, Outstanding Investigator Grants Now Available, CCSPs Changed To Program Projects

April 20, 1984

Amgen Claimed QOL Benefit Despite FDA Label Change.

May 18, 2007